| Property Name |
Property Value |
Unit |
Raw Value |
Raw Unit |
Annotation |
Factor |
Reference |
| AUC |
27290.0 |
ng.h/ml |
27.29±4.72 |
mg.h/l |
PO, oral; |
|
DRUGBANK |
AUC |
55040.0 |
ng.h/ml |
55.04±12.68 |
mg.h/l |
PO, oral; |
|
DRUGBANK |
| Bioavailability |
60.0 |
% |
~60 |
% |
|
|
DRUGBANK |
Bioavailability |
93.0 |
% |
93±10 |
% |
PO, oral; |
|
The Pharmacological Basis of Therapeutics |
Bioavailability |
50.0 |
% |
50 |
% |
PO, oral; |
|
The Pharmacological Basis of Therapeutics |
| C Max |
3930.0 |
ng/ml |
3.93±1.13 |
mg/L |
PO, oral; |
|
DRUGBANK |
C Max |
11210.0 |
ng/ml |
11.21±3.42 |
mg/L |
PO, oral; |
|
DRUGBANK |
C Max |
46000.0 |
ng/ml |
46±12 |
mcg/ml |
intravenous injection, IV; Elderly; normal,healthy; |
|
The Pharmacological Basis of Therapeutics |
C Max |
5000.0 |
ng/ml |
5.0 |
mcg/ml |
Oral single dose; adults; |
|
The Pharmacological Basis of Therapeutics |
| T Max |
1.3 |
h |
1.31±0.33 |
h |
PO, oral; |
|
DRUGBANK |
T Max |
1.5 |
h |
1.52±0.40 |
h |
PO, oral; |
|
DRUGBANK |
T Max |
1.5 |
h |
1-2 |
h |
PO, oral; |
|
The Pharmacological Basis of Therapeutics |
| Clearance |
21.3 |
L/h |
21.3 |
L/h |
Average clearance; |
|
DRUGBANK |
Clearance |
0.16 |
L/h/kg |
2.6±0.4 |
ml/min/kg |
|
Children → ;Elderly ↓ ;RD, renal impairment, Renal disease,including uremia ↓ ;normal renal function → ; |
The Pharmacological Basis of Therapeutics |
Clearance |
0.20 |
L/h/kg |
3.3 |
ml/min/kg |
intravenous injection, IV; human, homo sapiens; |
|
Human Intravenous Pharmacokinetic Dataset |
| Volume of Distribution |
22.7 |
L |
22.7 |
L |
Total volume of distribution; |
|
DRUGBANK |
Volume of Distribution |
0.21 |
L/kg |
0.21±0.03 |
L/kg |
|
Elderly → ;RD, renal impairment, Renal disease,including uremia → ; |
The Pharmacological Basis of Therapeutics |
Volume of Distribution |
0.25 |
L/kg |
0.25 |
L/kg |
intravenous injection, IV; human, homo sapiens; |
|
Human Intravenous Pharmacokinetic Dataset |
| Half-life |
1.0 |
h |
61.3 |
min |
|
|
DRUGBANK |
Half-life |
1.7 |
h |
1.7±0.3 |
h |
|
Children → ;RD, renal impairment, Renal disease,including uremia ↑ ;Age ↑ ; |
The Pharmacological Basis of Therapeutics |
Half-life |
1.1 |
h |
1.1 |
h |
intravenous injection, IV; human, homo sapiens; |
|
Human Intravenous Pharmacokinetic Dataset |
| Eliminate Route |
74.0 |
% |
70-78 |
% |
Urinary excretion; |
|
DRUGBANK |
Eliminate Route |
86.0 |
% |
86±8 |
% |
Urinary excretion; Unchanged drug; |
|
The Pharmacological Basis of Therapeutics |
| Protein Binding |
17.0 |
% |
~17 |
% |
|
|
DRUGBANK |
Protein Binding |
18.0 |
% |
18 |
% |
|
|
The Pharmacological Basis of Therapeutics |